-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NeErk+/VFpbceCLJFZQovoBesnogddruy9djOj9c0t9ZsH6HxBLoWBwakHN4NwZm
 IQAC1JUBmOCr52syS+NTPw==

<SEC-DOCUMENT>0001144204-04-023213.txt : 20041230
<SEC-HEADER>0001144204-04-023213.hdr.sgml : 20041230
<ACCEPTANCE-DATETIME>20041230171718
ACCESSION NUMBER:		0001144204-04-023213
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20041228
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041230
DATE AS OF CHANGE:		20041230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SWISS MEDICA INC
		CENTRAL INDEX KEY:			0000318245
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980355519
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-09489
		FILM NUMBER:		041234843

	BUSINESS ADDRESS:	
		STREET 1:		53 YONGE STREET, 3RD FLOOR
		STREET 2:		TORONTO
		CITY:			ONTARIO, CANADA
		STATE:			A1
		ZIP:			M5E 1J3
		BUSINESS PHONE:		416-657-4134

	MAIL ADDRESS:	
		STREET 1:		53 YONGE STREET, 3RD FLOOR
		STREET 2:		TORONTO
		CITY:			ONTARIO, CANADA
		STATE:			A1
		ZIP:			M5E 1J3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SWISS MEDIA INC
		DATE OF NAME CHANGE:	20030702

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLOBAL PATH INC
		DATE OF NAME CHANGE:	20010814

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YOURNET INC/
		DATE OF NAME CHANGE:	19991108
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v010624.txt
<TEXT>

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                               ------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) of the
                         SECURITIES EXCHANGE ACT OF 1934

                                December 28, 2004

                               SWISS MEDICA, INC.
               (Exact Name of Registrant as Specified in Charter)


          Delaware                     000-09489               98-0355519
(State or other jurisdiction          (Commission             (IRS Employer
      of incorporation)              File Number)          Identification No.)


53 Yonge Street Third Floor, Toronto, Ontario, Canada              M5E 1J73
      (Address of principal executive offices)                    (Zip code)

 Registrant's telephone number, including area code:            (416) 868-0202

                                 Not Applicable
          (Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
<PAGE>

Item 5.02. Departure of Directors or Principal Officers; Appointment of
Principal Officers

            (b)

            Effective December 28, 2004, Raghu Kilambi resigned as the Chief
Financial Officer of Swiss Medica, Inc. (the "Company"). Mr. Kilambi will
continue to be the Company's Chief Executive Officer and director.

            (c)

            (1) Effective December 28, 2004, Bruce Fairbairn was appointed as
the Chief Financial Officer of the Company.

            (2) Mr. Fairbairn has been the Company's Controller (part-time)
since June 2003, controlling costs and building the accounting and budgeting
systems. From 2000 to June 2003, Mr. Fairbairn was a financial consultant to
mid-sized companies in the early growth stages. Prior to that, Mr. Fairbairn was
responsible for all of the day-to-day operations of a privately-held
corporation, including: financial reporting, cash flow analysis and control and
implementation of maintenance of operating controls and procedures. Mr.
Fairbairn graduated from McGill University with a Bachelors degree in Commerce.

            (3) The Company and Mr. Fairbairn are currently negotiating a
definitive agreement relating to Mr. Fairbairn's employment with the Company.

Item. 8.01. Other Events.


            On December 28, 2004, the Company issued a press release announcing
that the Company appointed Mr. Fairbairn as its Chief Financial Officer. Item
9.01. Financial Statements and Exhibits.

            (a) Not applicable

            (b) Not applicable

            (c) Exhibit No. Description

<TABLE>
<CAPTION>
Exhibit          Description                                                           Location
- ------------     ---------------                                                       -----------
<S>              <C>                                                                   <C>
                 Press Release dated  December 28, 2004  announcing  Chief  Financial
Exhibit 99.1     Officer appointment                                                   Provided herewith
</TABLE>


                                       2
<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:    December 30, 2004                    SWISS MEDICA, INC.


                                              By: /s/ Raghu Kilambi
                                                  ------------------------------
                                              Name:   Raghu Kilambi
                                              Title:   Chief Executive Officer


                                       3

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v010624_ex99-1.txt
<TEXT>
                                  EXHIBIT 99.1

Swiss Medica Announces Chief Financial Officer Appointment
Tuesday December 28, 8:00 am ET

TORONTO--(BUSINESS WIRE)--Dec. 28, 2004--Swiss Medica Inc. (OTC BB: SWME - News)

Chief Executive Officer Raghu Kilambi is pleased to announce the appointment of
Bruce Fairbairn as Swiss Medica's Chief Financial Officer, effective
immediately. "Mr. Fairbairn has been Swiss Medica's Controller (part-time) since
June 2003, controlling costs and building the accounting and budgeting systems,"
said Raghu Kilambi. "Mr. Fairbairn will take over full-time duties as Chief
Financial Officer while I continue as CEO. With Swiss Medica's expanded launch
into the United States, I will focus my CEO duties on overall corporate
performance, marketing strategies, corporate finance, investor relations and
public relations as we move into an accelerated growth phase during 2005."

Bruce Fairbairn brings nearly 30 years of proven experience as a financial
analyst, internal auditor and Chief Financial Officer. After graduating from
McGill University with a Bachelors degree in Commerce, Mr. Fairbairn served in
various financial capacities at the Canadian subsidiaries of NYSE-listed
companies such as Crane Company and Alcan Inc. He has also served as Chief
Financial Officer or in a senior financial position for privately owned firms,
such as Air Niagara, Range Transportation and Evergreen Peripherals.

Bruce Fairbairn said, "I am delighted to be joining such a vibrant team as we
continue to launch a product that is not only effective, but is also a safe and
natural solution to a problem affecting millions of people. This is a rare
opportunity that I could not resist."

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic
ailments. We increase our market share through focused distribution strategies
in multiple sales channels. Swiss Medica's mission is to be a world leader in
the commercialization of life enhancing bioscience products that improve quality
of lives. Please visit our websites at www.swissmedica.com and www.O24zone.com

Swiss Medica's flagship product, the O24(TM) Essential Oil Pain Neutralizer,
holds US Patent #6,444,238B1. The O24(TM) pain relief solution has been used,
recommended and praised for its fast-acting and long-lasting benefits by
healthcare professionals in the United States, Canada and in Europe. O24 is
widely available throughout Canada in leading pharmacies and natural food
stores. It is available in Happy Harry's Discount Drugstores in the United
States, and elsewhere by visiting www.O24zone.com, for ordering details and
store locators.

Forward-looking statements in this news release are made pursuant to the "Safe
Harbor" provisions of the United States Private Securities Litigation Reform Act
of 1995. Investors are cautioned that such forward-looking statements involve
risks and uncertainties, including, without limitation, risks relating to the
ability to close transactions being contemplated, risks related to international
sales and potential foreign currency exchange fluctuations, continued acceptance
of Swiss Medica's products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks detailed
from time to time in Swiss Medica's periodic reports filed with the United
States Securities and Exchange Commission and other regulatory authorities.


Swiss Medica Inc. (OTC Bulletin Board:SWME - News)
Contact:

     Swiss Medica
     Investor Relations Contact: David Jones
     1 (866) 485-4243
     OR
     Blue Skye PR, Inc.
     Press Contact: Sky Wallen
     (813) 732-6869
     blueskyeinc@yahoo.com

                                       4


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
